Pancreatic Cancer Research

ResearcherAmsterdam University Medical CentersActive in the last 2 years

Tanja D. de Gruijl

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1464-8978; OpenAlex author ID A5053105927. Sources: OpenAlex.

Their work

Papers
10 (first author 0, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
18
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: 2 papers · 2020: 1 paper · 2021: 3 papers · 2022: none · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper

Papers 10

  1. Systemic immunomodulation by irreversible electroporation versus stereotactic ablative body radiotherapy in locally advanced pancreatic cancer: the CROSSFIRE t… Last author DOI 10.1136/jitc-2024-010222↗
  2. MRI-guided stereotactic ablative body radiotherapy versus CT-guided percutaneous irreversible electroporation for locally advanced pancreatic cancer (CROSSFIRE… Co-author DOI 10.1016/s2468-1253(24)00017-7↗
  3. Tissue Resistance Decrease during Irreversible Electroporation of Pancreatic Cancer as a Biomarker for the Adaptive Immune Response and Survival. Co-author DOI 10.1016/j.jvir.2023.06.027↗
  4. Locally Advanced Pancreatic Cancer: Percutaneous Management Using Ablation, Brachytherapy, Intra-arterial Chemotherapy, and Intra-tumoral Immunotherapy. Co-author DOI 10.1007/s11912-021-01057-3↗
  5. Irreversible Electroporation and Nivolumab Combined with Intratumoral Administration of a Toll-Like Receptor Ligand, as a Means of In Vivo Vaccination for Meta… Co-author DOI 10.3390/cancers13153902↗
  6. Pancreatic Cancer and Immunotherapy: A Clinical Overview. Last author DOI 10.3390/cancers13164138↗
  7. Percutaneous Irreversible Electroporation in Locally Advanced and Recurrent Pancreatic Cancer (PANFIRE-2): A Multicenter, Prospective, Single-Arm, Phase II Stu… Co-author DOI 10.1148/radiol.2019191109↗
  8. Irreversible electroporation of locally advanced pancreatic cancer transiently alleviates immune suppression and creates a window for antitumor T cell activati… Last author DOI 10.1080/2162402x.2019.1652532↗
  9. Needle-guided ablation of locally advanced pancreatic cancer: cytoreduction or immunomodulation by in vivo vaccination? Co-author DOI 10.21037/cco.2019.10.05↗
  10. Ablation of Locally Advanced Pancreatic Cancer with Percutaneous Irreversible Electroporation: Results of the Phase I/II PANFIRE Study. Co-author DOI 10.1148/radiol.2016152835↗

Closest collaborators

The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hester J. Scheffer · 10 shared papers, 2017–2025 · strength 1.21
  2. Martijn Ruben Meijerink · 10 shared papers, 2017–2025 · strength 1.21
  3. Bart Geboers · 9 shared papers, 2019–2025 · strength 1.16
  4. Alette H. Ruarus · 7 shared papers, 2019–2025 · strength 0.92
  5. Florentine E. F. Timmer · 6 shared papers, 2021–2025 · strength 0.86
  6. Laurien G. P. H. Vroomen · 5 shared papers, 2017–2025 · strength 0.61
  7. Anna M E Bruynzeel · 3 shared papers, 2021–2025 · strength 0.48
  8. Frank J. Lagerwaard · 2 shared papers, 2024–2025 · strength 0.37
  9. Geert Kazemier M · 3 shared papers, 2017–2020 · strength 0.24
  10. Johanna W. Wilmink · 2 shared papers, 2021 · strength 0.22
  11. Babs M. Zonderhuis · 2 shared papers, 2017–2020 · strength 0.15
  12. Marc G. Besselink · 2 shared papers, 2017–2020 · strength 0.15
  13. Krijn P. van Lienden · 1 shared paper, 2020 · strength 0.10
  14. Eran van Veldhuisen · 1 shared paper, 2020 · strength 0.10
  15. Marian A.E. de van der Schueren · 1 shared paper, 2017 · strength 0.06
  16. Freek D. Daams · 1 shared paper, 2017 · strength 0.06
  17. Jantien A. Vogel · 1 shared paper, 2017 · strength 0.06
  18. Jill E. Witvliet-van Nierop · 1 shared paper, 2017 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.